MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

Molecular Cancer Therapeutics

Volumn 7, Issue 4, 2008, Pages 759-768

  Fournel, Marielle ^a   Bonfils, Claire ^a,b   Hou, Yu ^a   Yan, Pu Theresa ^a   Trachy Bourget, Marie Claude ^a   Kalita, Ann ^a   Liu, Jianhong ^a   Lu, Ai Hua ^a   Zhou, Nancy Z ^a   Robert, Marie France ^a   Gillespie, Jeffrey ^a   Wang, James J ^a   Ste Croix, Hélène ^a   Rahil, Jubrail ^a   Lefebvre, Sylvain ^a   Moradei, Oscar ^a   Delorme, Daniel ^a   MacLeod, A Robert ^a,c   Besterman, Jeffrey M ^a   Li, Zuomei ^a  

^a METHYLGENE INC   (Canada)

^b Neurochem Inc   (Canada)

^c Takeda San Diego Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 11; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; PROTEIN P21; UNCLASSIFIED DRUG; VORINOSTAT;

ACETYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG INHIBITION; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR XENOGRAFT;

ACETYLATION; ANIMALS; APOPTOSIS; BENZAMIDES; CELL PROLIFERATION; ENZYME INHIBITORS; FEMALE; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; ISOENZYMES; LUNG NEOPLASMS; MICE; MICE, NUDE; PYRIMIDINES; REPRESSOR PROTEINS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 42249084230     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-2026     Document Type: Article

References (50)

1. Gray SG, Ekstrom TJ. The human histone deacetylase family. Exp Cell Res 2001;262:75-83.
2. Thiagalingam S, Cheng KH, Lee HJ, Mineva N, Thiagalingam A, Ponte JF. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann N Y Acad Sci 2003;983:84-100.
3. Denu JM. The Sir 2 family of protein deacetylases. Curr Opin Chem Biol 2005;9:431-40.
4. Buck SW, Gallo CM, Smith JS. Diversity in the Sir2 family of protein deacetylases. J Leukoc Biol 2004;75:939-50.
5. Taunton J, Hassig CA, Schreiber SL. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science New York N Y 1996;272:408-11.
6. Yang WM, Inouye C, Zeng Y, Bearss D, Seto E. Transcriptional repression by YY1 is mediated by interaction with a mammalian homolog of the yeast global regulator RPD3. Proc Natl Acad Sci U S A 1996;93:12845-50.
7. Yang WM, Yao YL, Sun JM, Davie JR, Seto E. Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family. J Biol Chem 1997;272:28001-7.
8. Van den Wyngaert I, de Vries W, Kremer A, et al. Cloning and characterization of human histone deacetylase 8. FEBS Lett 2000;478:77-83.
9. Hu E, Chen Z, Fredrickson T, et al. Cloning and characterization of a novel human class I histone deacetylase that functions as a transcription repressor. J Biol Chem 2000;275:15254-64.
10. Fischle W, Emiliani S, Hendzel MJ, et al. A new family of human histone deacetylases related to Saccharomyces cerevisiae HDA1p. J Biol Chem 1999;274:11713-20.
11. Grozinger CM, Hassig CA, Schreiber SL. Three proteins define a class of human histone deacetylases related to yeast Hda1p. Proc Natl Acad Sci U S A 1999;96:4868-73.
12. Wang AH, Bertos NR, Vezmar M, et al. HDAC4, a human histone deacetylase related to yeast HDA1, is a transcriptional corepressor. Mol Cell Biol 1999;19:7816-27.
13. Kao HY, Downes M, Ordentlich P, Evans RM. Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression. Genes Dev 2000;14:55-66.
14. Zhou X, Marks PA, Rifkind RA, Richon VM. Cloning and characterization of a histone deacetylase, HDAC9. Proc Natl Acad Sci U S A 2001;98:10572-7.
15. Kao HY, Lee CH, Komarov A, Han CC, Evans RM. Isolation and characterization of mammalian HDAC10, a novel histone deacetylase. J Biol Chem 2002;277:187-93.
16. Gao L, Cueto MA, Asselbergs F, Atadja P. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J Biol Chem 2002;277:25748-55.
17. Fraga MF, Ballestar E, Villar-Garea A, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005;37:391-400.
18. Choi JH, Kwon HJ, Yoon BI, et al. Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res 2001;92:1300-4.
19. Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 2004;59:177-89.
20. Kawai H, Li H, Avraham S, Jiang S, Avraham HK. Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor a. Int J Cancer 2003;107:353-8.
21. Wilson AJ, Byun DS, Popova N, et al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 2006;281:13548-58.
22. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Gottlicher M. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 2004;5:455-63.
23. Melnick A, Licht JD. Histone deacetylases as therapeutic targets in hematologic malignancies. Curr Opin Hematol 2002;9:322-32.
24. Altucci L, Clarke N, Nebbioso A, Scognamiglio A, Gronemeyer H. Acute myeloid leukemia: therapeutic impact of epigenetic drugs. Int J Biochem Cell Biol 2005;37:1752-62.
25. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev 2002;1:287-99.
26. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001;1:194-202.
27. Monneret C. Histone deacetylase inhibitors for epigenetic therapy of cancer. Anticancer Drugs 2007;18:363-70.
28. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone-deacetylase inhibitors. Nat Rev 2006;5:769-84.
29. Kelly WK, Marks PA. Drug insight: histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract 2005;2:150-7.
30. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6:38-51.
31. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007;26:5541-52.
32. Richon VM, Emiliani S, Verdin E, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A 1998;95:3003-7.
33. George P, Bali P, Annavarapu S, et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 2005;105:1768-76.
34. Plumb JA, Finn PW, Williams RJ, et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2003;2:721-8.
35. Furumai R, Matsuyama A, Kobashi N, et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 2002;62:4916-21.
36. Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene 2007;26:1351-6.
37. Saito A, Yamashita T, Mariko Y, et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci U S A 1999;96:4592-7.
38. Hu E, Dul E, Sung CM, et al. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther 2003;307:720-8.
39. Karagiannis TC, El-Osta A. Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds? Leukemia 2007;21:61-5.
40. Zweidler A. Resolution of histones by polyacrylamide gel electrophoresis in presence of nonionic detergents. Methods Cell Biol 1978;17:223-33.
41. Glaser KB, Li J, Staver MJ, Wei RQ, Albert DH, Davidsen SK. Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem Biophys Res Commun 2003;310:529-36.
42. Lagger G, O'Carroll D, Rembold M, et al. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J 2002;21:2672-81.
43. Senese S, Zaragoza K, Minardi S, et al. Role for histone deacetylase 1 in human tumor cell proliferation. Mol Cell Biol 2007;27:4784-95.
44. Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ 2005;12:395-404.
45. Butler LM, Agus DB, Scher HI, et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 2000;60:5165-70.
46. Beckers T, Burkhardt C, Wieland H, et al. Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int J Cancer 2007;121:1138-48.
47. Finnin MS, Donigian JR, Cohen A, et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999;401:188-93.
48. Moradei OM, Mallais TC, Frechette S, et al. Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J Med Chem 2007;50:5543-6.
49. Garcia-Manero G, Minden M, Estrov Z, et al. Clinical activity and safety of the histone deacetylase inhibitor MGCD0103: results of a phase I study in patients with leukemia or myelodysplastic syndromes (MDS). 2006 ASCO Annual Meeting. J Clin Oncol 2006;24:6500.
50. Younes A, Fanale M, Pro B, et al. A phase II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor in patients with relapsed or refractory Hodgkin lymphoma. 2007 ASCO Annual Meeting. J Clin Oncol 2007;25:8000.